Volume 87 Issue 41 | p. 26 | Concentrates
Issue Date: October 12, 2009

Carbogen, Nextpharma Link Drug Services

Department: Business
Keywords: API, highly-potent compounds, dosage form

Carbogen Amcis and NextPharma Technologies are forming an alliance to combine Carbogen’s highly potent active pharmaceutical ingredient (API) manufacturing capabilities in Switzerland with NextPharma’s dosage-form drug-manufacturing services, which it offers from seven sites across North America and Europe. API manufacturer Lonza seeks to create a similar combined service through its planned acquisition of Patheon (C&EN, Aug. 31, page 10).

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society